93P Real-world analysis of first-line maintenance (1LM) immunotherapy (IO) +/- pemetrexed for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic

Abstract

Background: Real-world analyses of 1LM IO +/- pemetrexed for patients (pts) with NSQ a/mNSCLC, including the relative impact of 1LM pemetrexed in this setting, are lacking. Here we report a retrospective analysis of 1LM treatment patterns and their outcomes in NSQ a/mNSCLC prior to/during the COVID-19 pandemic in the UK.